FibroGen's Upcoming Presentation at a Major Summit
FibroGen, Inc. (NASDAQ: FGEN) is set to take center stage at a pivotal event, the Oppenheimer Movers in Rare Disease Summit. This significant gathering will take place in a prominent city and will showcase the latest advancements in addressing rare diseases.
Spotlight on Thane Wettig's Leadership
As Chief Executive Officer, Thane Wettig from FibroGen will feature prominently in a panel discussion entitled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts. This session is scheduled for Thursday, and it promises to be an insightful dialogue on the future of therapies aimed at rare diseases.
Investors' Opportunity for Interaction
In addition to the panel, FibroGen's esteemed management team will be available for personalized one-on-one meetings throughout the summit. This presents an excellent opportunity for interested investors to engage directly and discuss potential collaborations and developments in the industry.
About FibroGen and Its Innovative Therapies
Founded with a mission to transform patient care in critical areas such as cancer biology and anemia treatment, FibroGen continues to break ground with its cutting-edge therapies. Roxadustat is one of the front-running products, already approved in several markets for treating anemia associated with chronic kidney disease (CKD), demonstrating strong clinical results.
The company is actively exploring further applications, including a Phase 3 trial for roxadustat in patients with lower-risk myelodysplastic syndrome (LR-MDS) in the United States. On the horizon is FG-3246, a pioneering antibody-drug conjugate (ADC) focused on targeting CD46, which is currently in Phase 2 development for metastatic castration-resistant prostate cancer. This project is complemented by FG-3180, a promising biomarker development associated with CD46.
Encouraging Future Developments
With such an impactful portfolio, FibroGen is strategically positioned to make substantial contributions to the field of rare diseases. The presentations and interactions at the Oppenheimer Movers in Rare Disease Summit will not only showcase these innovative therapies but also reinforce FibroGen's commitment to advancing patient treatment options.
Contact for Investor Inquiries
For additional information or inquiries, interested parties can reach out to David DeLucia, CFA, who serves as the Senior Vice President and Chief Financial Officer. He is available to address any questions related to FibroGen's ongoing projects and financial outlook through direct communication.
How to Get in Touch
David can be contacted via email for investor inquiries. This opens the door for discussions on how FibroGen's pioneering work may align with potential investors' interests.
Frequently Asked Questions
What is the Oppenheimer Movers in Rare Disease Summit?
The Oppenheimer Movers in Rare Disease Summit is a key event that highlights advancements and innovations in the treatment of rare diseases, featuring various industry leaders.
Who will represent FibroGen at the summit?
Thane Wettig, the CEO of FibroGen, will represent the company and participate in pivotal discussions about the future of rare disease therapies.
What is Roxadustat?
Roxadustat is a novel therapy developed by FibroGen for treating anemia associated with chronic kidney disease, currently approved in multiple markets.
What upcoming trials is FibroGen pursuing?
FibroGen is working on a Phase 3 trial for roxadustat in patients with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. along with other promising developments.
How can investors get in touch with FibroGen?
Investors can contact David DeLucia, the CFO, via email for inquiries and discussions regarding investment opportunities and the company's direction.
